Zobrazeno 1 - 10 of 613 pro vyhledávání: '"Michael W Deininger"'
1
Akademický článek
Mapping the Evidence for Opioid-Mediated Changes in Malignancy and Chemotherapeutic Efficacy: Protocol for a Scoping Review
Autor: Jonathan E Constance, Mary M McFarland, Tallie Casucci, Michael W Deininger, Elena Y Enioutina, Kathleen Job, Richard S Lemons, Carol S Lim, Robert M Ward, Venkata Yellepeddi, Kevin M Watt
Publikováno v: JMIR Research Protocols, Vol 12, p e38167 (2023)
BackgroundNumerous reports contend opioids can augment or inhibit malignancy. At present, there is no consensus on the risk or benefit posed by opioids on malignancy or chemotherapeutic activity. Distinguishing the consequences of opioid use from pai
Externí odkaz: https://doaj.org/article/01de88bf0bb141f3bfea67eaff1c11ed
Zobrazit plný text záznamu
3
Akademický článek
A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.
Autor: Kara J Johnson, Ian J Griswold, Thomas O'Hare, Amie S Corbin, Marc Loriaux, Michael W Deininger, Brian J Druker
Publikováno v: PLoS ONE, Vol 4, Iss 10, p e7439 (2009)
The BCR-ABL tyrosine kinase is the defining feature of chronic myeloid leukemia (CML) and its kinase activity is required for induction of this disease. Current thinking holds that BCR-ABL forms a multi-protein complex that incorporates several subst
Externí odkaz: https://doaj.org/article/c64c26d7b6684ec8a1f2e29e5a84ed15
Zobrazit plný text záznamu
4
Akademický článek
ERK2, but not ERK1, mediates acquired and 'de novo' resistance to imatinib mesylate: implication for CML therapy.
Autor: Clara I Aceves-Luquero, Anupriya Agarwal, Juan L Callejas-Valera, Laura Arias-González, Azucena Esparís-Ogando, Luis del Peso Ovalle, Itxaso Bellón-Echeverria, Miguel A de la Cruz-Morcillo, Eva M Galán Moya, Inmaculada Moreno Gimeno, Juan C Gómez, Michael W Deininger, Atanasio Pandiella, Ricardo Sánchez Prieto
Publikováno v: PLoS ONE, Vol 4, Iss 7, p e6124 (2009)
Resistance to Imatinib Mesylate (IM) is a major problem in Chronic Myelogenous Leukaemia management. Most of the studies about resistance have focused on point mutations on BCR/ABL. However, other types of resistance that do not imply mutations in BC
Externí odkaz: https://doaj.org/article/3dff57472bb442969456148bb3804193
Zobrazit plný text záznamu
5
Akademický článek
The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations
Autor: Anca Franzini, Anthony D. Pomicter, Dongqing Yan, Jamshid S. Khorashad, Srinivas K. Tantravahi, Hein Than, Jonathan M. Ahmann, Thomas O'Hare, Michael W. Deininger
Publikováno v: Blood Advances, Vol 3, Iss 20, Pp 2949-2961 (2019)
Abstract: Chronic myelomonocytic leukemia (CMML) is an aggressive myeloid neoplasm of older individuals characterized by persistent monocytosis. Somatic mutations in CMML are heterogeneous and only partially explain the variability in clinical outcom
Externí odkaz: https://doaj.org/article/30e9e7d7553a4fbba5ecb5c38bde1cc7
Zobrazit plný text záznamu
6
Akademický článek
Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature
Autor: Sigal Tavor, Tali Shalit, Noa Chapal Ilani, Yoni Moskovitz, Nir Livnat, Yoram Groner, Haim Barr, Mark D. Minden, Alexander Plotnikov, Michael W. Deininger, Nathali Kaushansky, Liran I. Shlush
Publikováno v: Haematologica, Vol 105, Iss 12 (2020)
Novel targeted therapies demonstrate improved survival in specific subgroups (defined by genetic variants) of acute myeloid leukemia (AML) patients, validating the paradigm of molecularly targeted therapy. However, identifying correlations between AM
Externí odkaz: https://doaj.org/article/bbb351a6ca2341a399bd41c89409281d
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje